Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · ai

Latham Advises GSK on US$110 Million Research Collaboration With Relation Therapeutics

1 August 2026 · By · Wire by Fusion42

Published

1 August 2026

Topic

ai

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at lw.com →

◆ Verified

Fusion42 · 1 August 2026 · Fusion42 review

GSK and Relation Therapeutics have entered a US$110 million research collaboration to generate human cellular datasets and train AI foundational models for drug discovery, building on previous partnerships in fibrotic disease and osteoarthritis.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

AI-driven drug discovery has advanced with big pharma funding large-scale human cellular data projects. Founders in biotech and AI should use this window to pitch AI integration with biologic data to pharma partners.

◆ Coverage

1 source · 1 Aug 2026

◆ Related on Wire

◆ Topics

Biotechaidrug-discoverybiotech-collaborationhuman-cellular-data